It’s shaping up to be an expensive few years for Johnson & Johnson.
On Oct. 9, a Philadelphia judge ordered the pharmaceutical and CPG behemoth to pay $8 billion to 26-year-old Nicholas Murray, who claimed that Risperdal, an anti-psychotic drug manufactured by J&J’s pharmaceutical subsidiary Janssen, made him grow breasts.
Murray’s lawyers claimed Johnson & Johnson did not properly warn that breast growth could be a side effect of the drug, and argued the company put “profits over patients” in marketing Risperdal.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in